Yixing Jiang, MD
Basic profileUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Yixing Jiang is an Oncology physician affiliated with University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. OpenAlex indexes 118 publications with 3,553 citations (h-index 27); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St
Baltimore, MD 212011544
Telephone
410-328-6841Registry record last updated 13 Feb 2015.
Clinical trials
- Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Sponsor: Milton S. Hershey Medical Center
Overall officialPhase 1CompletedNCT00565487
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Intera Oncology, IncProgram year20251 payment
- ACCORD HEALTHCARE, INC.Program year20251 payment
- Incyte CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
37.1%Opioid Agonist24.6%Oxycodone Hcl78%Hydromorphone Hcl22%Part D<11 patientsPhenothiazine12.5%Prochlorperazine Maleate100%Part D≥17 patientsMetabolism & gastrointestinal
30.5%Serotonin-3 Receptor Antagonist14.1%Ondansetron Hcl100%Part D≥20 patientsPotassium supplement6.6%Potassium Chloride100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
16.4%Kinase inhibitor16.4%Imatinib Mesylate71%Pemazyre29%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase I study of the ceramide nanoliposome in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology
2023 - BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Molecular Cancer Research
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gorgun Akpek, MD, MHS
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Saul Yanovich
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Mohammad A. Khan
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Petr Hausner, MD
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”